These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 25418950)
21. Development of Conductivity Method as an Alternative to Titration for Hydrolytic Resistance Testing Used for Evaluation of Glass Vials Used in Pharmaceutical Industry. Fujimori K; Lee H; Phillips J; Nashed-Samuel Y PDA J Pharm Sci Technol; 2017 1/2; 71(1):50-58. PubMed ID: 27593692 [TBL] [Abstract][Full Text] [Related]
22. Particulate Study on NeoProfen, a Neonatal Injectable Product. Krishna A; Rice M; Kester T; Waters M; Wilson T PDA J Pharm Sci Technol; 2016; 70(1):76-92. PubMed ID: 26889056 [TBL] [Abstract][Full Text] [Related]
23. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Mahler HC; Müller R; Friess W; Delille A; Matheus S Eur J Pharm Biopharm; 2005 Apr; 59(3):407-17. PubMed ID: 15760721 [TBL] [Abstract][Full Text] [Related]
24. Shipping-Induced Aggregation in Therapeutic Antibodies: Utilization of a Scale-Down Model to Assess Degradation in Monoclonal Antibodies. Fleischman ML; Chung J; Paul EP; Lewus RA J Pharm Sci; 2017 Apr; 106(4):994-1000. PubMed ID: 27964939 [TBL] [Abstract][Full Text] [Related]
25. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466 [TBL] [Abstract][Full Text] [Related]
26. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation. Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478 [TBL] [Abstract][Full Text] [Related]
28. Influence of methionine oxidation on the aggregation of recombinant human growth hormone. Mulinacci F; Poirier E; Capelle MA; Gurny R; Arvinte T Eur J Pharm Biopharm; 2013 Sep; 85(1):42-52. PubMed ID: 23958317 [TBL] [Abstract][Full Text] [Related]
29. Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions. Snell JR; Zhou C; Carpenter JF; Randolph TW J Pharm Sci; 2016 Oct; 105(10):3057-3063. PubMed ID: 27488901 [TBL] [Abstract][Full Text] [Related]
30. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis. Zhang K; Wrzosek T; Desai KG; Monck M PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785 [TBL] [Abstract][Full Text] [Related]
31. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600 [TBL] [Abstract][Full Text] [Related]
32. No Touching! Abrasion of Adsorbed Protein Is the Root Cause of Subvisible Particle Formation During Stirring. Sediq AS; van Duijvenvoorde RB; Jiskoot W; Nejadnik MR J Pharm Sci; 2016 Feb; 105(2):519-529. PubMed ID: 26869415 [TBL] [Abstract][Full Text] [Related]
33. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS. Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006 [TBL] [Abstract][Full Text] [Related]